A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma

Investigational New Drugs

Volumn 18, Issue 2, 2000, Pages 193-197

  Small, Eric J ^a,b,c,d,e,f   Figlin, Robert ^a,b,c,d,e,f   Petrylak, Daniel ^a,b,c,d,e,f   Vaughn, David J ^a,b,c,d,e,f   Sartor, Oliver ^a,b,c,d,e,f   Horak, Ivan ^a,b,c,d,e,f   Pincus, Rosemarie ^a,b,c,d,e,f   Kremer, Alton ^a,b,c,d,e,f   Bowden, Chris ^a,b,c,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NewYork Presbyterian Columbia University Irving Medical Center   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^f Oncology Clinical Research and Development   (United States)

Author keywords

Duocarmycins; Kidney cancer; KW 2189

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; PIBROZELESIN;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG INFUSION; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; KIDNEY CARCINOMA; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; RIGOR; THROMBOCYTOPENIA; TREATMENT FAILURE; VERTIGO; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLIDINONES;

EID: 0034060914     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006386115312     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1998. CA Cancer J Clin 48: 6-29, 1998
2. Yagoda A, Bassam AR, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993. Sernin Oncol 22: 42-60, 1995
3. Motzer RJ, Bander NH, Manus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996
4. Negrier S, Excudier B, Lasset C, Douillard J-Y, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338: 1271-1278, 1998
5. Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, et al.: Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential non-randomized phase II study. J Clin Oncol 16: 2502-2513, 1998
6. Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, et al.: Subcutaneous interleukin-2, interferon Alfa-2a, and continuous infusion of fluorouacil in metastatic renal cell carcinoma: A multicenter phase II trial. J Clin Oncol 16: 2728-2732, 1998
7. Naglieri E, Gebbia V, Durini E, Lellil G, Abbate 1, et al.: Standard interleukin-2 (IL-2) and interferon alfa immunotherapy versus an IL-2 and 4-epirubicin immunochemotherapeutic association in metastatic renal cell carcinoma. Anticancer Res 18: 2021-2026, 1998
8. Elsasser-Beile U, Koble N, Grussenmeyer T, Wetterauer U, Schultze-Seeman W: Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin-2, interferon alfa and retinoic acid. Anticancer Res 18: 1883-1890, 1998
9. Creagan ET, Hestorff RD, Suman VJ, Mailliard JA, Nair S, et al.: Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma. Am J Clin Oncol 21: 139-141, 1998
10. Henriksson R, Nilsson S, Colleen S, Wersail P, Helsing M, Zimmerman R, Engman K: Survival in renal cell carcinoma - a randomized evaluation of tarnoxifen versus interleukin 2, alfa-interferon (leucocyte) and tamoxifen. Br J Cancer 77: 1311-1317, 1998
11. Yasuzawa T, Iida T, Muroi KI, Ichimura M, Takahashi K, Sano H: Structures of duocarmycins, novel antitumor antibiotics produced by streptomyces sp., Chem Pharm Bull 36: 3728-3731, 1988
12. Gorni K, Kobayashi E, Miyoshi K, Ashizawa T, Okamoto A, Ogawa T, Katsumata S, Nfihara A, Okabe M, Hirate T: Anticellular and antitumor activity of duocarmycins, novel antibiotics. Jpn J Cancer Res 83: 113-120, 1992
13. Asai A, Nagarnura S, Saito H: A novel property of duocarmycin and its analogues for covalent reaction with DNA. J Am Chem Soc 116: 4171-4177, 1994
14. Asai A, Nagamura S, Saito H, Takahashi 1, Nakano H: The reversible DNA-alkylating activity of duocarmycin and its analogues. Nuc Acids Res 22: 88-93, 1994
15. Boger DL, Johnson DS. CC- 1065 and the duocarmycins: Unraveling the keys to a new class of naturally derived alkylating agents. Proc Natl Acad Sci USA 92: 3642-3649, 1995
16. Okamoto A, Okabe M, Gomi K: Analysis of DNA fragmentation in human uterine cervix carcinoma S3 cells treated with duocarmycins or other antitumor agents by pulse field gel electrophoresis. Jpn J Cancer Res 84: 93-98, 1993
17. Vaughn DJ, Tempero M, Singh K, Lee P, Pesco-Koplowitz L, Kremer A, Horak ID: Phase I clinical pharmacokinetics study of duocamycin B2 analog (KW2189) in patients with pancreatic and gastric carcinoma. Proc Am Soc Clin Oncol 16: 309, 1997
18. Kobayashi E, Okamoto A, Adada M, Okabe M, Nagarnura S, Asai A, Saito H, Gorni K, Hirata A: Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin against murine and human tumors. Cancer Res 54: 2402-2410, 1994
19. Ogasawara H, Nishio K, Takeda Y, Ohmori T, Kubota N, Funayama Y, Ohira T, et al.: A novel antibiotic (KW-2189) is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells. Jpn J Cancer Res 85: 418-425, 1994
20. Okamoto A, Asai A, Saito H, Okabe M, Gomi K: Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells. Jpn J Cancer Res 85: 1304-1311, 1994
21. Ogasawara Y, Nishio K, Ogasawara F, Nishio K, Kanzawa F, Lee Y-S, Funayama Y, et al.: Intracellular carboxyl esterase activity is a determinant if cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT- 11. Jpn J Cancer Res 86: 124-129, 1995
22. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V: The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci American 4: 162-167, 1998
23. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH: Phase I study of adozelesin administered by 24-hour continuous infusion. JNCI 86: 368-371, 1994
24. Wolff 1, Bench K, Beijnen JH, Bruntsch U, Cavelli F, Jong JD, et al.: Phase I clinical and pharmacological study of Carzelesin (U-80244) given daily for five consecutive days. Clin Cancer Res 2: 1717-1723, 1996